Medtronic.jpeg” />

Irish medical technology firm Medtronic has obtained the US Food and Drug Administration (FDA) approval for its Melody transcatheter pulmonary valve (TPV) for use in patients whose surgical bioprosthetic pulmonary heart valves have failed.

The new TPV is designed for the pulmonic position to prolong the time between open-heart surgeries for patients with a dysfunctional right ventricular outflow tract (RVOT) conduit caused by congenital heart disease (CHD).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Intended to be a minimally invasive treatment option, the valve is placed inside a failing pulmonic surgical heart valve through a low-profile, delivery catheter called Ensemble II delivery system that is specifically designed to deliver the TPV.

Medtronic Heart Valve Therapies business vice-president and general manager Rhonda Robb said: "Unlike other transcatheter valves currently on the market, Melody TPV is uniquely designed for use in the pulmonic position and is thus well suited for implantation in failed surgical pulmonary heart valves.

"This approval further demonstrates our commitment to improving treatment options for congenital heart disease and we look forward to bringing this proven non-surgical option to congenital patients."

"Melody TPV is uniquely designed for use in the pulmonic position and is thus well suited for implantation in failed surgical pulmonary heart valves."

While the transcatheter has received CE mark in September 2006, it was launched in the US in 2010, and has been implanted in more than 10,500 patients till date.

Seperately, the company has also secured expanded 510(k) clearance from the FDA for its Kyphon Xpede bone cement to fix pathological fractures of the sacral vertebral body or ala through sacral vertebroplasty or sacroplasty.

The bone cement was previously indicated for treatment of vertebral fractures associated with osteoporosis, cancer or benign lesions.

Image: Melody transcatheter pulmonary valve. Photo: courtesy of Medtronic.